ARCHIVES

Biotherapeutics Reports LAK/IL-2 Toxicity Reduced With Constant Infusion Of IL-2

This article is from The Cancer Letter archive.

Vol. 13 No. 16 | April 17, 1987

Download PDF Visit The Full Archive

Related Articles

Cancer Policy; Board Suggests More Detailed Items In Tobacco Agreement

August 22, 1997

CCI Gets Qualified Approval To Continue

January 18, 1980

Penn Begins Clinical Trial Of A Vaccine For Breast Cancer Based On Telomerase

February 27, 2004

The Cancer Letter Obtains “Confidential” Documents From Duke IRB Investigation

May 14, 2010

Amgen’s Aranesp Sales Dropped By Half, Continue To Fall.

November 14, 2008

ORI finds Hopkins Coordinator Falsified Information On Grant

May 16, 1997